146 related articles for article (PubMed ID: 22992372)
1. Integration of ERα-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer.
Bennani-Baiti IM
Breast Cancer Res; 2012 Sep; 14(5):112. PubMed ID: 22992372
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Cortez V; Mann M; Tekmal S; Suzuki T; Miyata N; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Vadlamudi RK
Breast Cancer Res; 2012 Jul; 14(4):R108. PubMed ID: 22812534
[TBL] [Abstract][Full Text] [Related]
3. Significance of ER-Src axis in hormonal therapy resistance.
Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
[TBL] [Abstract][Full Text] [Related]
4. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
5. Negative regulation of ERα by a novel protein CAC1 through association with histone demethylase LSD1.
Kim J; Park UH; Moon M; Um SJ; Kim EJ
FEBS Lett; 2013 Jan; 587(1):17-22. PubMed ID: 23178685
[TBL] [Abstract][Full Text] [Related]
6. LSD1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP.
Bennesch MA; Segala G; Wider D; Picard D
Nucleic Acids Res; 2016 Oct; 44(18):8655-8670. PubMed ID: 27325688
[TBL] [Abstract][Full Text] [Related]
7. PELP1 oncogenic functions involve alternative splicing via PRMT6.
Mann M; Zou Y; Chen Y; Brann D; Vadlamudi R
Mol Oncol; 2014 Mar; 8(2):389-400. PubMed ID: 24447537
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal growth factor receptor 2 inhibits activating transcription factor 7 to promote breast cancer cell migration by activating histone lysine demethylase 1.
Lin J; Mao H; Ji Z; Lin W; Wang T
J Cancer Res Ther; 2021 Nov; 17(5):1192-1201. PubMed ID: 34850767
[TBL] [Abstract][Full Text] [Related]
9. Regulation of aromatase induction by nuclear receptor coregulator PELP1.
Vadlamudi RK; Rajhans R; Chakravarty D; Nair BC; Nair SS; Evans DB; Chen S; Tekmal RR
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):211-8. PubMed ID: 19800002
[TBL] [Abstract][Full Text] [Related]
10. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity.
Nair SS; Nair BC; Cortez V; Chakravarty D; Metzger E; Schüle R; Brann DW; Tekmal RR; Vadlamudi RK
EMBO Rep; 2010 Jun; 11(6):438-44. PubMed ID: 20448663
[TBL] [Abstract][Full Text] [Related]
11. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Rajhans R; Nair HB; Nair SS; Cortez V; Ikuko K; Kirma NB; Zhou D; Holden AE; Brann DW; Chen S; Tekmal RR; Vadlamudi RK
Mol Endocrinol; 2008 Mar; 22(3):649-64. PubMed ID: 18079323
[TBL] [Abstract][Full Text] [Related]
12. Interaction of transcription factor AP-2 gamma with proto-oncogene PELP1 promotes tumorigenesis by enhancing RET signaling.
Liu J; Liu Z; Li M; Tang W; Pratap UP; Luo Y; Altwegg KA; Li X; Zou Y; Zhu H; Sareddy GR; Viswanadhapalli S; Vadlamudi RK
Mol Oncol; 2021 Apr; 15(4):1146-1161. PubMed ID: 33269540
[TBL] [Abstract][Full Text] [Related]
13. Significance of PELP1 in ER-negative breast cancer metastasis.
Roy S; Chakravarty D; Cortez V; De Mukhopadhyay K; Bandyopadhyay A; Ahn JM; Raj GV; Tekmal RR; Sun L; Vadlamudi RK
Mol Cancer Res; 2012 Jan; 10(1):25-33. PubMed ID: 22086908
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of neuronal Lysine-Specific Demethylase 1LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2.
Toffolo E; Rusconi F; Paganini L; Tortorici M; Pilotto S; Heise C; Verpelli C; Tedeschi G; Maffioli E; Sala C; Mattevi A; Battaglioli E
J Neurochem; 2014 Mar; 128(5):603-16. PubMed ID: 24111946
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic PELP1 and ERRgamma protect human mammary epithelial cells from Tam-induced cell death.
Girard BJ; Regan Anderson TM; Welch SL; Nicely J; Seewaldt VL; Ostrander JH
PLoS One; 2015; 10(3):e0121206. PubMed ID: 25789479
[TBL] [Abstract][Full Text] [Related]
16. PELP1: Structure, biological function and clinical significance.
Sareddy GR; Vadlamudi RK
Gene; 2016 Jul; 585(1):128-134. PubMed ID: 26997260
[TBL] [Abstract][Full Text] [Related]
17. Extranuclear coactivator signaling confers insensitivity to tamoxifen.
Kumar R; Zhang H; Holm C; Vadlamudi RK; Landberg G; Rayala SK
Clin Cancer Res; 2009 Jun; 15(12):4123-30. PubMed ID: 19470742
[TBL] [Abstract][Full Text] [Related]
18. E239K mutation abolishes the suppressive effects of lysine-specific demethylase 1 on migration and invasion of MCF7 cells.
Zhang Y; Wu T; Zhao B; Liu Z; Qian R; Zhang J; Shi Y; Wan Y; Li Z; Hu X
Cancer Sci; 2022 Feb; 113(2):489-499. PubMed ID: 34839571
[TBL] [Abstract][Full Text] [Related]
19. Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and -independent manners.
Pollock JA; Larrea MD; Jasper JS; McDonnell DP; McCafferty DG
ACS Chem Biol; 2012 Jul; 7(7):1221-31. PubMed ID: 22533360
[TBL] [Abstract][Full Text] [Related]
20. PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.
Cortez V; Samayoa C; Zamora A; Martinez L; Tekmal RR; Vadlamudi RK
Cancer Res; 2014 Dec; 74(24):7395-405. PubMed ID: 25377474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
